Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuwellis, Inc. filings document a Nasdaq-listed medical technology issuer focused on cardiorenal care and ultrafiltration therapy. Form 8-K reports cover operating results, material events, clinical or regulatory disclosures, board appointments and resignations, and resolved litigation matters, while proxy materials describe director elections, auditor ratification, board committee governance, executive compensation, and stockholder voting matters.
Nuwellis, Inc. director Emerson J. Martin received a grant of nonstatutory stock options as part of his equity compensation. The award covers 6,744 options to buy Nuwellis common stock at an exercise price of $1.16 per share.
The options vest in 12 approximately equal monthly installments starting one month after the grant date, so they are fully vested after one year. The options expire on April 27, 2036 if not exercised. After this grant, Martin holds 6,744 derivative securities related to Nuwellis common stock directly.
Nuwellis, Inc. director Archelle Georgiou Feldshon received a grant of nonstatutory stock options covering 6,744 shares of common stock. The options have an exercise price of $1.16 per share and expire on April 27, 2036.
The award vests in 12 approximately equal monthly installments starting one month after the grant date, so all 6,744 options will be fully vested on the one-year anniversary of the grant. This is a compensation-related equity grant, not an open-market share purchase or sale.
Nuwellis, Inc. director David McDonald received a grant of nonstatutory stock options covering 6,744 shares of common stock. The options have an exercise price of $1.16 per share and expire on April 27, 2036. They vest in 12 approximately equal monthly installments over one year.
Nuwellis, Inc. held its annual stockholder meeting where investors elected two Class I directors and approved the company’s auditor for 2026. Marty J. Emerson and David A. McDonald were elected to three-year terms ending at the 2029 annual meeting.
Stockholders also ratified Baker Tilly US, LLP as Nuwellis’ independent registered public accounting firm for the fiscal year ending December 31, 2026. A total of 1,078,020 common shares, representing approximately 43.81% of shares outstanding as of the record date, were represented virtually or by proxy.
Nuwellis, Inc. has settled a contract dispute with E.F. Hutton & Co. over an engagement letter related to registered securities offerings. Under a Settlement Agreement and Release dated April 24, 2026, Nuwellis agreed to pay $204,000 to Hutton within five days.
The agreement includes no admission of liability, mutual releases of all claims, and an obligation for Hutton to file a stipulation to dismiss the lawsuit with prejudice within two days after receiving the settlement payment.
Nuwellis, Inc. is asking stockholders to vote at its 2026 annual meeting, to be held virtually on April 28, 2026 at 2:00 p.m. U.S. Central Time. Holders of common stock at the March 24, 2026 record date, when 2,635,718 shares were outstanding, may participate and vote.
Stockholders are being asked to elect two Class I directors, Martin Emerson and David McDonald, to terms running to the 2029 meeting, and to approve on an advisory basis the appointment of Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026. The board recommends voting FOR all director nominees and FOR the auditor ratification.
Nuwellis, Inc. filed an amended current report to update an earlier disclosure about board resignations. This Amendment No. 1 adds as exhibits supplemental response letters from former directors Katharyn Field and Mika Grasso addressing the company’s initial description of their March 26, 2026 resignations.
The company states it does not agree with certain statements in these response letters and maintains that its original account in the initial filing is accurate. Nuwellis emphasizes that the resignation and response letters reflect only the former directors’ personal views and may conflict with management’s and the board’s views.
The company cautions that it does not take responsibility for the contents of the former directors’ letters and encourages stockholders and investors to rely on information in its official SEC reports, including its most recent annual and quarterly reports.
Nuwellis, Inc. director Emerson Martin J filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a director and provides a baseline disclosure of his equity relationship with the company. The report does not list any specific transactions or holdings in the provided data.